Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
86.50
+3.02 (3.62%)
Feb 6, 2026, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,069 employees as of December 31, 2024. The number of employees increased by 142 or 15.32% compared to the previous year.
Employees
1,069
Change (1Y)
142
Growth (1Y)
15.32%
Revenue / Employee
$904,543
Profits / Employee
-$239,796
Market Cap
14.01B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | 660 | -97 | -12.81% |
| Dec 31, 2020 | 757 | -60 | -7.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 5,800 |
| Bio-Techne | 3,100 |
| BioMarin Pharmaceutical | 3,040 |
| Exelixis | 1,147 |
| Ascendis Pharma | 1,017 |
| Revolution Medicines | 809 |
| Roivant Sciences | 750 |
| BridgeBio Pharma | 730 |
IONS News
- 19 days ago - DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE) - Business Wire
- 19 days ago - Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth - Seeking Alpha
- 26 days ago - Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts - Business Wire
- 4 weeks ago - GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Benzinga
- 4 weeks ago - Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B - Business Wire
- 4 weeks ago - Ionis to present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) - Business Wire